Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Protein Family May Help in Cancer Therapy

By BiotechDaily International staff writers
Posted on 19 Aug 2013
British researchers have discovered the key role played by a group of proteins in the process of mitosis. Figuring out how to regulate them may give scientists a way to kill cancerous cells.

The study, published by investigators from Warwick Medical School (Coventry, UK) on August 5, 2013, in the Journal of Cell Biology, emphasized the role of a newly identified team of proteins, TACC3-ch-TOG-clathrin, in forming inter-microtubule bridges that stabilize the kinetochore fibers (K-fibers) used in mitosis. When a cell divides, it generates a mitotic spindle that then makes sure that the chromosomes are divided equally between the two new cells. Failure to do so effectively can lead to complications; those cells with either too few or too many chromosomes are at risk of becoming cancerous.

To achieve this, the mitotic spindle uses K-fibers to allow for chromosome traveling around the cell. These fibers are made up of even smaller microtubules, bundled together by what may be termed “bridges,” which is where the team of proteins comes in. Clathrin is a protein that is involved in the process of membrane operating in interphase cells, but it changes roles during mitosis and localizes to the mitotic spindle where it works with TACC3 and ch-TOG to form these bridges. When TACC3 is taken from the cell, the clathrin is no longer able to bind the microtubules. Other bridges do exist but they only represent approximately 40% of the total so the microtubules, and as a result the mitotic spindle, are considerably feebler. By developing technology to rapidly remove the team of proteins, the researchers have been able to determine that removing TACC3 allows the scientists to force the cells to die.

Prof. Royle explained, “That sounds like a negative—the idea of a cell dying. However it’s vital to remember that most adult cells are no longer dividing and what we are suggesting is being able to shut down mitosis in those that are multiplying.”

There are other functions tied to cell division that would need to be taken into account, such as repairing damage, but Dr. Royle confidently believes that this is still a significant move forward in destroying cancerous cells. He added, “Though it isn’t yet capable of being fully targeted to kill only cancerous cells, neither are the current treatments. Existing drugs like taxanes, for example, do not discriminate between cancerous cells and normal cells. Hopefully the next development will allow us to use a greater understanding of how this team of proteins can be used in a more clinical environment.”

Related Links:

Warwick Medical School



Channels

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.